Which ASX 200 company director just sold $480 million worth of shares?

The mammoth trade follows the release of hundreds of millions of ASX shares from voluntary escrow post-merger.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Chemist Warehouse co-founder Jack Gance has just sold $480.8 million worth of Sigma Healthcare Ltd (ASX: SIG) shares.

The mammoth transaction was revealed in a 'Change of Director's Interest Notice' that Sigma lodged with the ASX this week.

According to The Australian, Gance hired Macquarie Capital to orchestrate the off-market sale.

Gance sold 155.1 million Sigma Healthcare shares for $3.10 per share.

A surprised and curious male investor drinks black coffee while reading the latest news on rising ASX shares in the newspaper

Image source: Getty Images

Why did Gance sell 155 million Sigma Healthcare shares?

The motivation for Gance's trade is unknown.

However, it occurred within 24 hours of 157.9 million shares belonging to Gance being released from voluntary escrow.

The trade occurred last Thursday, 24 hours after about 558.1 million Sigma Healthcare shares were released from voluntary escrow.

Those shares belong to Gance and his fellow Chemist Warehouse co-founders, Sam Gance and the CEO, Mario Verrocchi.

Sigma and Chemist Warehouse announced their merger in December 2023, and the deal was completed on 12 February this year.

The trio entered a voluntary escrow arrangement at the time of the merger's completion.

In a statement on the day the merger was completed, Sigma Healthcare said the trio had entered a voluntary escrow arrangement because they "are committed to the long-term value creation opportunities available to Sigma following implementation of the Scheme".

In total, 5.6 billion Sigma Healthcare shares were put into voluntary escrow for the trio.

There were two periods of escrow.

The First Period was defined as between the merger completion and the earlier of 31 August or the close of trading on the day Sigma Healthcare released its FY25 results.

This First Period of escrow involved about 558.1 million Sigma Healthcare shares.

The Second Period is between the end of the First Period and the earlier of either 31 August 2026 or the close of trading on the day Sigma releases its FY26 results.

This Second Period applies to 90% of the escrowed Sigma Healthcare shares.

Sigma Healthcare released its FY25 results last Wednesday, 27 August, which signalled the end of the First Period of escrow.

The Australian reports that Jack Gance's $480.8 million sell-off occurred after the close of trading on Thursday, 28 August.

Is the $480 million sell-off cause for concern?

Despite the mega sale, Jack Gance still has plenty of skin in the game at Sigma Healthcare.

Following the transaction, Gance still holds more than 1.42 million Sigma Healthcare shares, equating to a 12.34% stake.

The Sigma share price is $3.08, down 0.3% on Thursday, while the S&P/ASX 200 Index (ASX: XJO) is up 0.7%.

Sigma Healthcare is the ASX 200's second-largest healthcare stock with a market capitalisation of $35.67 billion.

Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Macquarie Group. The Motley Fool Australia has positions in and has recommended Macquarie Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

One girl leapfrogs over her friend's back.
Healthcare Shares

Could CSL shares double from here? Here's what the experts think

Experts remain divided despite CSL's sharp rebound from multi-year lows.

Read more »

Scientist looking at a laptop thinking about the share price performance.
Healthcare Shares

Here's why I'd buy and hold CSL and Cochlear shares for 10 years

The market is focused on the problems, but I think the decade-long opportunity still looks attractive.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Here's what brokers tip for CSL shares over the next 12 months

Can CSL shares keep climbing higher?

Read more »

A businessman holds his hand to his wide-open yawning mouth as he closes his eyes and makes a funny face while he gives a wholehearted yawn.
Broker Notes

How much could ResMed shares rise according to Morgans?

Current share price weakness could be an opportunity.

Read more »

Doctor checking patient's spine x-ray image.
Healthcare Shares

This healthcare stock just jumped 15% and experts are tipping a further 80% rise 

Momentum is building for this exciting stock.

Read more »

A smiling young couple sit with a finance professional at a computer, looking at the screen.
Healthcare Shares

3 reasons why the ASX share owner of Chemist Warehouse is a buy

I think Chemist Warehouse is a great business for a few reasons.

Read more »

A woman sits at her computer with her chin resting on her hand as she contemplates her next potential investment.
Healthcare Shares

How have CSL shares performed over 10 years?

Was it a good idea to buy the biotech giant's shares in 2016? Here are the returns.

Read more »

Young girl shows hearing aid while smiling.
Healthcare Shares

Cochlear shares have bounced 16%. Should you buy, hold, or sell now?

Analysts reveal whether Cochlear's recovery still has room to run.

Read more »